Ping Qiu

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), Changsha University, International Centre for Theoretical Physics Asia-Pacific, Huzhou Women and Children's Hospital, Hunan Agricultural University · ORCID：0000-0003-4090-5704

发表论文 162 篇 · 总被引 3566 次 · h-index 27

代表论文

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial (2023 · Journal of Clinical Oncology · 被引 140)
Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer (2024 · Gynecologic Oncology · 被引 21)
KMT2D links TGF ‐β signaling to noncanonical activin pathway and regulates pancreatic cancer cell plasticity (2023 · International Journal of Cancer · 被引 17)
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study (2024 · Prostate Cancer and Prostatic Diseases · 被引 15)
Effects of Somatostatin and Indomethacin Mono or Combination Therapy on High-risk Hyperamylasemia and Post-pancreatitis Endoscopic Retrograde Cholangiopancreatography Patients: A Randomized Study (2023 · Surgical Laparoscopy Endoscopy & Percutaneous Techniques · 被引 15)
Shen Qi Wan ameliorates nephritis in chronic kidney disease via AQP1 and DEFB1 regulation (2023 · Biomedicine & Pharmacotherapy · 被引 9)